Finance

Beta
Lists
7096:TYO
StemCell Institute Inc
¥677.00
+4.64%
(+30.00) 1D
Jun 5, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 7096...
Open
¥645
High
¥694
Low
¥645
Mkt. cap
6.94B
Avg. vol.
14.56K
Volume
16.10K
P/E ratio
43.85
52-wk high
¥1,245
52-wk low
¥627
EPS
¥15
No. of employees
117
Open
¥645
High
¥694
Low
¥645
Mkt. cap
6.94B
Avg. vol.
14.56K
Volume
16.10K
P/E ratio
43.85
52-wk high
¥1,245
52-wk low
¥627
EPS
¥15
No. of employees
117
News stories
From sources across the web
About StemCell Institute Inc
CEO-
Employees117
FoundedAug 5, 1999
Headquarters-
SectorHealth care provider
Websitestemcell.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
700.00M
715.00M
729.00M
667.00M
Cost of goods sold
269.00M
274.00M
279.00M
277.00M
Cost of revenue
269.00M
274.00M
279.00M
277.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
366.00M
375.00M
362.00M
406.00M
Operating expense
366.00M
375.00M
362.00M
406.00M
Total operating expenses
635.00M
649.00M
641.00M
683.00M
Operating income
65.00M
66.00M
88.00M
-16.00M
Other non operating income
-
-2.00M
-
1.00M
EBT including unusual items
67.00M
69.00M
92.00M
-11.00M
EBT excluding unusual items
67.00M
69.00M
92.00M
-11.00M
Income tax expense
24.00M
28.00M
32.00M
2.00M
Effective tax rate
35.82%
40.58%
34.78%
-18.18%
Other operating expenses
-
-
-
-
Net income
43.00M
41.00M
62.00M
9.00M
Net profit margin
6.14%
5.73%
8.50%
1.35%
Earnings per share
-
-
-
-
Interest and investment income
3.00M
6.00M
5.00M
6.00M
Interest expense
-1.00M
-1.00M
-1.00M
-2.00M
Net interest expenses
2.00M
5.00M
4.00M
4.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
97.00M
101.50M
120.00M
23.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer